WRF
VRTX icon

Waddell & Reed Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Waddell & Reed Financial’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$300M Buy
1,396,827
+10
+0% +$2.2K 0.62% 33
2020
Q4 		$330M Sell
1,396,817
-343,440
-20% -$78.8M 0.7% 28
2020
Q3 		$474M Sell
1,740,257
-18,171
-1% -$5.01M 1.14% 9
2020
Q2 		$510M Sell
1,758,428
-304,949
-15% -$82.7M 1.32% 7
2020
Q1 		$491M Sell
2,063,377
-243,878
-11% -$55.9M 1.6% 7
2019
Q4 		$505M Buy
2,307,255
+67,781
+3% +$13.7M 1.25% 8
2019
Q3 		$379M Buy
2,239,474
+4,829
+0.2% +$854K 0.98% 19
2019
Q2 		$410M Buy
2,234,645
+133,930
+6% +$23.4M 1.01% 17
2019
Q1 		$386M Sell
2,100,715
-70,342
-3% -$13M 0.96% 17
2018
Q4 		$360M Sell
2,171,057
-37,421
-2% -$6.48M 1.02% 14
2018
Q3 		$426M Sell
2,208,478
-19,877
-0.9% -$3.54M 0.94% 18
2018
Q2 		$379M Sell
2,228,355
-132,591
-6% -$20.6M 0.88% 22
2018
Q1 		$385M Sell
2,360,946
-497,901
-17% -$81.3M 0.87% 22
2017
Q4 		$428M Sell
2,858,847
-741,394
-21% -$110M 0.95% 18
2017
Q3 		$547M Sell
3,600,241
-426,182
-11% -$64.1M 1.22% 13
2017
Q2 		$519M Buy
4,026,423
+392,420
+11% +$47.2M 1.14% 15
2017
Q1 		$397M Sell
3,634,003
-214,602
-6% -$18.9M 0.84% 25
2016
Q4 		$284M Sell
3,848,605
-193,243
-5% -$15.7M 0.62% 41
2016
Q3 		$352M Sell
4,041,848
-216,630
-5% -$20.5M 0.73% 32
2016
Q2 		$366M Sell
4,258,478
-303,165
-7% -$26.2M 0.77% 31
2016
Q1 		$363M Sell
4,561,643
-426,120
-9% -$38.5M 0.68% 36
2015
Q4 		$628M Buy
4,987,763
+36,873
+0.7% +$4.45M 1.02% 21
2015
Q3 		$516M Buy
4,950,890
+215,016
+5% +$27.6M 0.85% 28
2015
Q2 		$585M Buy
4,735,874
+518,486
+12% +$65.3M 0.84% 32
2015
Q1 		$498M Buy
4,217,388
+385,088
+10% +$46.1M 0.69% 41
2014
Q4 		$455M Sell
3,832,300
-4,700
-0.1% -$529K 0.63% 46
2014
Q3 		$431M Buy
3,837,000
+28,200
+0.7% +$2.68M 0.6% 55
2014
Q2 		$361M Buy
3,808,800
+199,800
+6% +$14M 0.53% 63
2014
Q1 		$255M Buy
3,609,000
+43,300
+1% +$3.43M 0.39% 74
2013
Q4 		$265M Buy
3,565,700
+387,100
+12% +$27M 0.43% 69
2013
Q3 		$241M Buy
3,178,600
+267,500
+9% +$21.3M 0.46% 61
2013
Q2 		$233M Buy
+2,911,100
New +$214M 0.49% 57

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Waddell & Reed Financial's VRTX Position: Q1 2021 in Review

Waddell & Reed Financial increased its Vertex Pharmaceuticals (VRTX) stake by 0% in Q1 2021, buying an estimated $2.2K and bringing the position to 1,396,827 shares worth $300M. The position accounts for 0.62% of the portfolio, ranked #33.

Waddell & Reed Financial first reported a position in VRTX in Q2 2013 and has held it in 32 quarters since. The position peaked at $628M in Q4 2015. 999 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

  • Waddell & Reed Financial held 1,396,827 shares of Vertex Pharmaceuticals worth $300M as of Q1 2021.
  • Waddell & Reed Financial bought 10 Vertex Pharmaceuticals shares in Q1 2021, an estimated $2.2K.
  • Vertex Pharmaceuticals made up 0.62% of Waddell & Reed Financial's portfolio in Q1 2021, its #33 holding.
  • Waddell & Reed Financial first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 32 quarters since.
  • Waddell & Reed Financial's Vertex Pharmaceuticals position peaked at $628M in Q4 2015.
  • 999 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on Waddell & Reed Financial's 13F filing for Q1 2021, filed 12 May 2021.